Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 20/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16071621 | 0.93 | FGFR4 (1.00) | FGFR4 | |
| SCHEMBL16134070 | 0.91 | FGFR4 (0.97) | FGFR4 | |
| SCHEMBL16071806 | 0.91 | FGFR4 (0.84) | FGFR4 | |
| SCHEMBL16071512 | 0.90 | FGFR4 (0.82) | FGFR4 | |
| SCHEMBL16071965 | 0.90 | FGFR4 (1.00) | FGFR4 | |
| SCHEMBL16071437 | 0.90 | FGFR4 (1.00) | FGFR4 | |
| SCHEMBL16071730 | 0.90 | FGFR4 (1.00) | FGFR4 | |
| SCHEMBL16071628 | 0.89 | FGFR4 (1.00) | FGFR4 | |
| SCHEMBL16071395 | 0.89 | FGFR4 (1.00) | FGFR4 | |
| SCHEMBL16072322 | 0.89 | FGFR4 (1.00) | FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
| US-10189794-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-01-29 | — | — | US | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-08-04 | — | — | US | disclosed |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-08-04 | — | — | US | disclosed |
| US-9321786-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321786-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-18 | — | — | US | disclosed |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-18 | — | — | US | disclosed |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| WO-2014144737-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | FGFR4 1590/4885 |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | FGFR4 2623/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | FGFR4 2623/4885 |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | FGFR4 1590/4885 |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | FGFR4 2623/4885 |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | FGFR4 1220/4885 |
| US-10189794-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | FGFR4 2623/4885 |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | FGFR4 2623/4885 |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | FGFR4 2623/4885 |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | FGFR4 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.